MAZE up 180% YOY, but fund trims $3.1M stake post-Phase 2 data. Valuation high, risks loom.
RKT surges 118% on revenue beat, but market shrugs. LADR, FBRT, FLG miss estimates, stocks flat to down.
TYRA's 280% surge continues as HighVista adds shares. Preclinical biotech, no revenue, but strong cash runway.
ZBH revenue up 9.3% but stock drops 10.7%; STE revenue up 7.3%, stock up 4.6%. Mixed results.
Thames Water's £10B rescue deal faces political paralysis risk. Investors fear delays could push it to nationalization.
GPCR up 60% on obesity drug data, but HighVista sells $4.7M amid high valuation.
PGNY beats Q1 estimates on revenue & profit; margin expands despite lower sales volumes. Buy?
Sponsored
Must Read